Please login to order a test.
- Carboxyterminal Cross-linking Telopeptide of Bone Collagen
- Collagen Cross-linked C-Telopeptide
- Type 1 Collagen
For in vitro diagnostic use as an indicator of human bone resorption. This test may be used as an aid in monitoring bone resorption changes of antiresorptive therapies in postmenopausal women, individuals with osteopenia, and in predicting skeletal response (bone mineral density) in postmenopausal women undergoing antiresorptive therapies.
• Hormone replacement therapies (HRT) with hormones and hormone-like drugs
• Bisphosphonate therapies
This test is not intended to predict the development of osteoporosis or future fracture risk. The use of this test has not been established in hyperparathyroidism or hyperthyroidism. When using the test to monitor therapy, results may be confounded in patients afflicted with clinical conditions known to affect bone resorption (eg, bone metastases, hyperparathyroidism, or hyperthyroidism). Results should be interpreted in conjunction with clinical findings and other diagnostic results and should not be used as a sole determination in initiating or changing therapy. Note: Serum values are not interchangeable with urine values.
Electrochemiluminescence immunoassay (ECLIA)
It is recommended to draw blood as fasting, morning samples. Samples should not be taken from patients receiving therapy with high biotin doses (i.e. >5 mg/day) until at least 8 hours following the last biotin administration.
Separate serum from cells within 45 minutes of collection. Transfer specimen to a plastic transport tube before freezing. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.